We are live on ! Find out more
TPC

Takeda Pharmaceutical Company Portfolio holdings

AUM $16.4M
1-Year Est. Return 195.92%
This Fund
S&P 500
This Quarter Est. Return
-33.23%
1 Year Est. Return
+195.92%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$16.2M
AUM Growth
-$10.4M
Cap. Flow
$0
Cap. Flow %
0%
Top 10 Hldgs %
99.89%
Holding
11
New
–
Increased
–
Reduced
–
Closed
–

Top Buys

No buys this quarter

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HLVX
1
DELISTED
HilleVax
HLVX
$9.75M 60.21%
6,724,000
– –
OVID icon
2
Ovid Therapeutics
OVID
$489M
$2.35M 14.51%
7,531,996
– –
XLO icon
3
Xilio Therapeutics
XLO
$59.9M
$1.07M 6.6%
105,366
– –
EQ icon
4
Equillium
EQ
$138M
$712K 4.4%
1,824,977
– –
AMWL icon
5
American Well
AMWL
$221M
$613K 3.78%
77,733
– –
STTK icon
6
Shattuck Labs
STTK
$704M
$490K 3.02%
515,619
– –
LYEL icon
7
Lyell Immunopharma
LYEL
$330M
$443K 2.74%
41,166
– –
TSBX
8
DELISTED
Turnstone Biologics
TSBX
$367K 2.27%
895,824
– –
RANI icon
9
Rani Therapeutics
RANI
$87.7M
$256K 1.58%
203,190
– –
THRD
10
DELISTED
Third Harmonic Bio
THRD
$128K 0.79%
36,835
– –
LAB icon
11
Standard BioTools
LAB
$307M
$17.8K 0.11%
16,515
– –

Similar funds

KL
KCK Ltd Hamilton, Bermuda $15.1M AUM 30.14% 1-Year Est. Return
LM
Lasry Marc $15.1M AUM 10.39% 1-Year Est. Return
DADR
Dynamo Administracao de Recursos Rio De Janeiro, Brazil $18.5M AUM 37.41% 1-Year Est. Return
AVM
Avalon Ventures Management La Jolla, California $14.2M AUM 9.35% 1-Year Est. Return
RCMU
Rokos Capital Management (US) New York $14.2M AUM
PM
Pharo Management New York $18.7M AUM
SHM
Sagard Holdings Management Toronto, Ontario, Canada $20M AUM
SI
SQN Investors Menlo Park, California $12.8M AUM

Takeda Pharmaceutical Company's Q1 2025 Portfolio in Review

As of Q1 2025, Takeda Pharmaceutical Company held 11 positions worth $16.2M, down 39% from $26.6M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q1 2025: portfolio turnover was 0%. Takeda Pharmaceutical Company opened no new positions and made no exits, leaving the 11-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Takeda Pharmaceutical Company's ten largest holdings make up 100% of its $16.2M portfolio in Q1 2025.
  • Takeda Pharmaceutical Company opened 0 new positions and closed 0 in Q1 2025.
  • Takeda Pharmaceutical Company's portfolio value fell 39% quarter-over-quarter to $16.2M.

Based on Takeda Pharmaceutical Company's 13F filing for Q1 2025, filed 12 May 2025.